New Two-Drug attack on rare salivary gland cancers shows promise
NCT ID NCT04325828
Summary
This study is testing whether a drug called apalutamide, when given with a hormone-blocking injection, can shrink tumors in people with advanced salivary gland cancer. It is for patients whose cancer has spread or returned and whose tumors test positive for a specific protein called the androgen receptor. The main goal is to see how many participants' tumors shrink in response to this combination treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SALIVARY GLAND NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center Hospital
Nagoya, 464 8681, Japan
-
Hokkaido University Hospital
Sapporo, 060-8648, Japan
-
Kansai Medical University Hospital
Hirakata, 573 1191, Japan
-
National Cancer Center Hospital
Chūōku, 104 0045, Japan
-
National Hospital Organization Kyushu Medical Center
Fukuoka, 810 8563, Japan
-
National Hospital Organization Shikoku Cancer Center
Matsuyama, 791 0280, Japan
-
Niigata University Medical And Dental Hospital
Niigata, 951 8520, Japan
Conditions
Explore the condition pages connected to this study.